0.00Open0.05Pre Close0 Volume141 Open Interest4.00Strike Price0.00Turnover275.25%IV52.35%PremiumDec 20, 2024Expiry Date0.00Intrinsic Value100Multiplier9DDays to Expiry0.05Extrinsic Value100Contract SizeAmericanOptions Type-0.0307Delta0.0195Gamma165.80Leverage Ratio-0.0129Theta-0.0001Rho-5.10Eff Leverage0.0009Vega
Anavex Life Sciences Stock Discussion
Anavex Life Sciences to Report New Long-Term Oral Blarcamesine Phase IIb/III Alzheimer’s Disease Data at J.P. Morgan 2025 Healthcare Conference
Anavex Life Sciences (Nasdaq: AVXL) announced it will present new long-term data from the Phase IIb/III ATTENTION-AD Open-Label-Extension (OLE) trial for blarcamesine in early Alzheimer's disease at the J.P. Morgan 2025 Healthcare Conference. The presentation will showcase data from up to 144 weeks of continuous treatm...
hmmmmm 🤔 looks very similar throughout the market starting at 3 pm
No comment yet